Zhongzhi Pharmaceutical Holdings (HKG:3737) signed a $3 million investment agreement with US-based GABAeron, acquiring 11.5% of the latter's preferred stock, according to a Monday filing with the Hong Kong bourse.
GABAeron specializes in innovative therapies for Alzheimer's disease using stem-cell-derived interneurons to restore neural networks. The partnership aims to support clinical trials for Alzheimer's treatment targeting the apolipoprotein E4 gene.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。